This application is a competitive renewal of the Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Specialized Program in Research Excellence (SPORE). The Dana-Farber/Harvard Cancer Center Lung Cancer SPORE includes investigators from the Harvard-affiliated hospitals in Boston, Harvard Medical School, and the Harvard School of Public Health. This DF/HCC Lung Cancer SPORE will build on the strengths of established ongoing scientific investigation within the DF/HCC. Five major projects are proposed. Project 1 will use single nucleotide polymorphisms in germline DMA to examine their associations with patient outcome following treatment for non-small cell lung cancer. Project 2 will examine the transcription factors Foxa2 and the C/EBP family members in the pathogenesis and potential treatment of lung cancer. Project 3 plans to target erlotinib-resistant lung cancer with other tyrosine kinase inhibitors and irradiation to provide further information on effective combinations of targeted agents. Project 4 will characterize the effect of Hsp90 inhibitors in NSCLCs with different genomic changes to help identify patients who may benefit from this therapy. Project 5 will study the mechanisms of acquired resistance to epidermal growth factor receptor-targeted agents in cell lines and human trials for patients with lung cancer. The 4 cores established in 2003 integrate these Projects. These include 1) Tissue and Pathology Core, 2) Administration, Evaluation and Planning Core, 3) Biostatistics Core, 4) Genomics and Bioinformatics Core. This SPORE application describes a Development Research Program that includes our past performance and plan for selection of new projects. The Career Development Program describes our recipients and outlines the mechanism for the identification and support of talented young investigators in lung cancer. The Developmental Research and Career Development Programs will provide the focus for involvement of the community in planning and financial support of the DF/HCC Lung Cancer SPORE. The goal of the DF/HCC Lung Cancer SPORE is to continue the translation of biological and technological advances into clinically meaningful advances for patients with lung cancer and at risk for lung cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Program Officer
Ujhazy, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Sofer, Tamar; Schifano, Elizabeth D; Christiani, David C et al. (2017) Weighted pseudolikelihood for SNP set analysis with multiple secondary outcomes in case-control genetic association studies. Biometrics 73:1210-1220
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672
Kinsey, C Matthew; San José Estépar, Raul; van der Velden, Jos et al. (2017) Lower Pectoralis Muscle Area Is Associated with a Worse Overall Survival in Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev 26:38-43
Rangachari, Deepa; VanderLaan, Paul A; Shea, Meghan et al. (2017) Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ?50% Expression in Lung Adenocarcinoma. J Thorac Oncol 12:878-883
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
VanderLaan, Paul A; Rangachari, Deepa; Mockus, Susan M et al. (2017) Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer 106:17-21
Rangachari, Deepa; Le, Xiuning; Shea, Meghan et al. (2017) Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol 12:e175-e177
Ben Khedher, Soumaya; Neri, Monica; Papadopoulos, Alexandra et al. (2017) Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium. Int J Cancer 141:309-323
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2017) Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium. Sci Rep 7:825

Showing the most recent 10 out of 256 publications